Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025)

Keros Therapeutics filings provide 7 years of Total Current Liabilities readings, the most recent being $20.4 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 25.63% to $20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.4 million, a 25.63% decrease, with the full-year FY2025 number at $20.4 million, down 25.63% from a year prior.
  • Total Current Liabilities hit $20.4 million in Q4 2025 for Keros Therapeutics, down from $24.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $39.4 million in Q1 2025 to a low of $7.5 million in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $16.6 million (2022), compared with a mean of $19.1 million.
  • The widest YoY moves for Total Current Liabilities: up 110.38% in 2025, down 25.63% in 2025.
  • Keros Therapeutics' Total Current Liabilities stood at $11.8 million in 2021, then surged by 39.68% to $16.5 million in 2022, then soared by 47.3% to $24.4 million in 2023, then grew by 12.62% to $27.4 million in 2024, then dropped by 25.63% to $20.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $20.4 million (Q4 2025), $24.1 million (Q3 2025), and $34.7 million (Q2 2025) per Business Quant data.